Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

Interactive Features

Test Your Knowledge
Quiz: Does Lenalidomide Lack Therapeutic Utility in Patients With AML?
10/27/2021
True or false: Lenalidomide failed to demonstrate therapeutic benefits during standard induction therapy or improved survival outcomes for patients with AML, except for those with the SRSF2 genotype.
True or false: Lenalidomide failed to demonstrate therapeutic benefits during standard induction therapy or improved survival outcomes for patients with AML, except for those with the SRSF2 genotype.
True or false: Lenalidomide...
10/27/2021
Oncology
Test Your Knowledge
Quiz: Does Lenalidomide Lack Therapeutic Utility in Patients With AML?
10/27/2021
True or false: Lenalidomide failed to demonstrate therapeutic benefits during standard induction therapy or improved survival outcomes for patients with AML, except for those with the SRSF2 genotype.
True or false: Lenalidomide failed to demonstrate therapeutic benefits during standard induction therapy or improved survival outcomes for patients with AML, except for those with the SRSF2 genotype.
True or false: Lenalidomide...
10/27/2021
Oncology
Test Your Knowledge
Quiz: Which Quizartinib-Based Combo Improved Outcomes in AML, MDS?
10/08/2021
Which of the following combinations is effective and well tolerated in patients with FLT3-IDT-mutated AML or MDS?
Which of the following combinations is effective and well tolerated in patients with FLT3-IDT-mutated AML or MDS?
Which of the following...
10/08/2021
Oncology

Advertisement

Test Your Knowledge
Quiz: Does Oblimersen Improve Outcomes in AML?
10/06/2021
True or false: The addition of oblimersen to chemotherapy failed to improve remission rates, overall survival (OS), and outcomes of older AML patients.
True or false: The addition of oblimersen to chemotherapy failed to improve remission rates, overall survival (OS), and outcomes of older AML patients.
True or false: The addition of...
10/06/2021
Oncology
Test Your Knowledge
Quiz: Does Oblimersen Improve Outcomes in AML?
10/06/2021
True or false: The addition of oblimersen to chemotherapy failed to improve remission rates, overall survival (OS), and outcomes of older AML patients.
True or false: The addition of oblimersen to chemotherapy failed to improve remission rates, overall survival (OS), and outcomes of older AML patients.
True or false: The addition of...
10/06/2021
Oncology
Test Your Knowledge
Quiz: Does NGS Show Efficacy in AML?
08/31/2021
True or false: NGS was shown to be less effective in the detection of MRD in AML.
True or false: NGS was shown to be less effective in the detection of MRD in AML.
True or false: NGS was shown to...
08/31/2021
Oncology

Advertisement

Test Your Knowledge
Quiz: Does NGS Show Efficacy in AML?
08/31/2021
True or false: NGS was shown to be less effective in the detection of MRD in AML.
True or false: NGS was shown to be less effective in the detection of MRD in AML.
True or false: NGS was shown to...
08/31/2021
Oncology
Test Your Knowledge
Quiz: Does Venetoclax Plus Chemotherapy Improve OS in Patients With AML/MDS?
08/23/2021
True or false: According to the phase 2 CLIA study, venetoclax plus intensive chemotherapy demonstrates encouraging EFS and OS in patients with AML, MDS?
True or false: According to the phase 2 CLIA study, venetoclax plus intensive chemotherapy demonstrates encouraging EFS and OS in patients with AML, MDS?
True or false: According to the...
08/23/2021
Oncology
Quiz
Quiz: Does Venetoclax Plus Gilterinib Show Antileukemic Activity in AML?
08/13/2021
True or false: Venetoclax plus gilteritinib achieves high rates of mCRc and strong antileukemic activity in patients with FLT3-mutated AML.
True or false: Venetoclax plus gilteritinib achieves high rates of mCRc and strong antileukemic activity in patients with FLT3-mutated AML.
True or false: Venetoclax plus...
08/13/2021
Oncology

Advertisement

Quiz
Quiz: Does a mutNPM1 Status Correlate with Prognostic Favorability in AML?
08/05/2021
True or False: True or false: Clinical data suggests that patients with AML and a mutNPM1 gene mutation have favorable prognoses and improved survival outcomes.
True or False: True or false: Clinical data suggests that patients with AML and a mutNPM1 gene mutation have favorable prognoses and improved survival outcomes.
True or False: True or false:...
08/05/2021
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
FDA Approval
FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML
08/01/2024
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of...
08/01/2024
Oncology
News
Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
08/01/2024
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the...
08/01/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use